Debbie Rigby presents the latest in research news
In ARISTOTLE study, non-major bleeding was common and substantially less frequent with apixaban than with warfarin. Non-major bleeding was three times more common than major bleeding (12.1% vs 3.8%). Non-major bleeding was less frequent with apixaban (6.4 per 100 patient-years) than warfarin (9.4 per 100 patient-years). The most frequent sites of non-major bleeding were haematuria (16.4%), epistaxis (14.8%), gastrointestinal (13.3%), haematoma (11.5%) and bruising/ecchymosis (10.1%).
This Cochrane review supports the use of bisphosphonates to reduce the risk of vertebral fractures and the prevention and treatment of steroid-induced bone loss. There was high-certainty evidence that bisphosphonates are beneficial in reducing the risk of vertebral fractures with data extending to 24 months of use; and moderate-certainty evidence that bisphosphonates are beneficial in preventing and treating corticosteroid-induced bone loss at both the lumbar spine and femoral neck.
Cochrane Database of Systematic Reviews 2016, Issue 10.
A survey completed by 262 respondents has shown consumers need more education about the maximum daily dose, contraindications and potential side effects. Consumers involved in the survey were mostly older than 50 years of age, female, well-educated, and with adequate functional health literacy. The consumers completed the survey when buying two popular OTC ibuprofen-containing products (Nurofen™ or Nurofen Plus™).
Australian and New Zealand Journal of Public Health. doi:10.1111/1753-6405.12589
This was a retrospective cohort study of veteran patients (n=27) conducted at a pharmacist-managed cholesterol-optimisation clinic. Patients with low-serum vitamin D and a history of statin-induced myopathy received vitamin D replenishment prior to rechallenging statin therapy. All patients were able to maintain their statin therapy without myalgia after vitamin D supplementation.
Journal of Pharmacy Practice October 24, 2016